Differential gene expression in ovarian carcinoma: Identification of potential biomarkers

Kathleen Hibbs, Keith M Skubitz, Stefan E. Pambuccian, Rachael C. Casey, Kathryn M. Burleson, Theodore R. Oegema, Jeannine J. Thiele, Suzanne M. Grindle, Robin L. Bliss, Amy P Skubitz

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)397-414
Number of pages18
JournalAmerican Journal of Pathology
Volume165
Issue number2
DOIs
StatePublished - Jan 1 2004

Fingerprint

Biomarkers
Carcinoma
Gene Expression
Genes
Claudin-4
Ovary
Integrins
Bone Morphogenetic Protein 7
Retinoic Acid Receptors
Omentum
Calcium-Binding Proteins
Collagen Type II
Tumor Biomarkers
Ovarian Neoplasms
Cause of Death
Immunohistochemistry
Neoplasm Metastasis
Neoplasms
Proteins

Cite this

Differential gene expression in ovarian carcinoma : Identification of potential biomarkers. / Hibbs, Kathleen; Skubitz, Keith M; Pambuccian, Stefan E.; Casey, Rachael C.; Burleson, Kathryn M.; Oegema, Theodore R.; Thiele, Jeannine J.; Grindle, Suzanne M.; Bliss, Robin L.; Skubitz, Amy P.

In: American Journal of Pathology, Vol. 165, No. 2, 01.01.2004, p. 397-414.

Research output: Contribution to journalArticle

Hibbs, K, Skubitz, KM, Pambuccian, SE, Casey, RC, Burleson, KM, Oegema, TR, Thiele, JJ, Grindle, SM, Bliss, RL & Skubitz, AP 2004, 'Differential gene expression in ovarian carcinoma: Identification of potential biomarkers', American Journal of Pathology, vol. 165, no. 2, pp. 397-414. https://doi.org/10.1016/S0002-9440(10)63306-8
Hibbs, Kathleen ; Skubitz, Keith M ; Pambuccian, Stefan E. ; Casey, Rachael C. ; Burleson, Kathryn M. ; Oegema, Theodore R. ; Thiele, Jeannine J. ; Grindle, Suzanne M. ; Bliss, Robin L. ; Skubitz, Amy P. / Differential gene expression in ovarian carcinoma : Identification of potential biomarkers. In: American Journal of Pathology. 2004 ; Vol. 165, No. 2. pp. 397-414.
@article{8dca23d98dcd46f08d828571349d0f25,
title = "Differential gene expression in ovarian carcinoma: Identification of potential biomarkers",
abstract = "Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.",
author = "Kathleen Hibbs and Skubitz, {Keith M} and Pambuccian, {Stefan E.} and Casey, {Rachael C.} and Burleson, {Kathryn M.} and Oegema, {Theodore R.} and Thiele, {Jeannine J.} and Grindle, {Suzanne M.} and Bliss, {Robin L.} and Skubitz, {Amy P}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/S0002-9440(10)63306-8",
language = "English (US)",
volume = "165",
pages = "397--414",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Differential gene expression in ovarian carcinoma

T2 - Identification of potential biomarkers

AU - Hibbs, Kathleen

AU - Skubitz, Keith M

AU - Pambuccian, Stefan E.

AU - Casey, Rachael C.

AU - Burleson, Kathryn M.

AU - Oegema, Theodore R.

AU - Thiele, Jeannine J.

AU - Grindle, Suzanne M.

AU - Bliss, Robin L.

AU - Skubitz, Amy P

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.

AB - Ovarian cancer remains the fifth leading cause of cancer death for women in the United States. In this study, the gene expression of 20 ovarian carcinomas, 17 ovarian carcinomas metastatic to the omentum, and 50 normal ovaries was determined by Gene Logic Inc. using Affymetrix GeneChip HU_95 arrays containing ∼12,000 known genes. Differences in gene expression were quantified as fold changes in gene expression in ovarian carcinomas compared to normal ovaries and ovarian carcinoma metastases. Genes up-regulated in ovarian carcinoma tissue samples compared to more than 300 other normal and diseased tissue samples were identified. Seven genes were selected for further screening by immunohistochemistry to determine the presence and localization of the proteins. These seven genes were: the β8 integrin subunit, bone morphogenetic protein-7, claudin-4, collagen type IX α2, cellular retinoic acid binding protein-1, forkhead box J1, and S100 calcium-binding protein Al. Statistical analyses showed that the β8 integrin subunit, claudin-4, and S100A1 provided the best distinction between ovarian carcinoma and normal ovary tissues, and may serve as the best candidate tumor markers among the seven genes studied. These results suggest that further exploration into other up-regulated genes may identify novel diagnostic, therapeutic, and/or prognostic biomarkers in ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=3242813597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242813597&partnerID=8YFLogxK

U2 - 10.1016/S0002-9440(10)63306-8

DO - 10.1016/S0002-9440(10)63306-8

M3 - Article

C2 - 15277215

AN - SCOPUS:3242813597

VL - 165

SP - 397

EP - 414

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 2

ER -